|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
4104.00
|
|
|
52-Week-Low (Rs.)
|
3050.15
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 68.12 | 111.08 | 73.64 | 51.71 | 50.20 | CEPS(Rs) | 81.00 | 122.78 | 83.23 | 58.72 | 56.56 | DPS(Rs) | 30.00 | 30.00 | 20.00 | 16.00 | 16.00 | Book NAV/Share(Rs) | 478.64 | 440.44 | 349.28 | 275.63 | 262.70 | Tax Rate(%) | 23.19 | 19.80 | 25.62 | 24.30 | 27.31 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 30.60 | 43.42 | 41.36 | 33.83 | 37.60 | EBIT Margin(%) | 30.69 | 41.22 | 38.56 | 33.91 | 37.35 | Pre Tax Margin(%) | 30.66 | 41.20 | 38.53 | 33.77 | 37.26 | PAT Margin (%) | 23.55 | 33.04 | 28.66 | 25.57 | 27.08 | Cash Profit Margin (%) | 28.01 | 36.52 | 32.39 | 29.03 | 30.52 | Performance Ratios | | | | | | ROA(%) | 12.32 | 22.76 | 18.84 | 15.08 | 15.52 | ROE(%) | 14.82 | 28.13 | 23.57 | 19.21 | 20.61 | ROCE(%) | 19.31 | 35.09 | 31.64 | 25.23 | 28.06 | Asset Turnover(x) | 0.52 | 0.69 | 0.66 | 0.59 | 0.57 | Sales/Fixed Asset(x) | 1.28 | 1.73 | 1.66 | 1.75 | 1.97 | Working Capital/Sales(x) | 0.94 | 1.25 | 1.35 | 1.43 | 1.29 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.78 | 0.58 | 0.60 | 0.57 | 0.51 | Receivable days | 107.79 | 88.26 | 87.73 | 95.70 | 88.81 | Inventory Days | 128.95 | 95.85 | 101.33 | 115.82 | 109.22 | Payable days | 91.20 | 92.79 | 107.07 | 92.94 | 88.28 | Valuation Parameters | | | | | | PER(x) | 41.48 | 39.65 | 49.30 | 38.43 | 33.93 | PCE(x) | 34.88 | 35.87 | 43.61 | 33.85 | 30.11 | Price/Book(x) | 5.90 | 10.00 | 10.39 | 7.21 | 6.48 | Yield(%) | 1.06 | 0.68 | 0.55 | 0.81 | 0.94 | EV/Net Sales(x) | 9.29 | 12.85 | 13.86 | 9.92 | 9.27 | EV/Core EBITDA(x) | 26.25 | 28.60 | 32.67 | 26.26 | 22.53 | EV/EBIT(x) | 30.06 | 31.02 | 35.83 | 28.94 | 24.60 | EV/CE(x) | 4.79 | 7.83 | 8.31 | 5.60 | 5.14 | M Cap / Sales | 9.84 | 13.16 | 14.17 | 9.93 | 9.27 | Growth Ratio | | | | | | Net Sales Growth(%) | -14.13 | 30.61 | 28.02 | 8.83 | 27.88 | Core EBITDA Growth(%) | -32.36 | 38.29 | 43.77 | -0.02 | 47.11 | EBIT Growth(%) | -35.95 | 39.87 | 44.46 | -0.95 | 50.44 | PAT Growth(%) | -38.68 | 50.84 | 42.40 | 3.01 | 53.25 | EPS Growth(%) | -38.68 | 50.84 | 42.40 | 3.01 | 53.25 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | Current Ratio(x) | 6.40 | 3.94 | 3.95 | 3.09 | 5.58 | Quick Ratio(x) | 4.56 | 2.85 | 2.76 | 2.12 | 3.58 | Interest Cover(x) | 1,393.96 | 2,126.16 | 1,452.86 | 258.94 | 398.66 | Total Debt/Mcap(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|
|
|
|